Few words can cause such fear and anxiety. Whether the cancer is associated
with smoking (bronchogenic) or not (adenocarcinoma), the survival statistics
are not good.
In 2010, the CDC recorded the following statistics[i]:
And in 2012, the SEER database reported that 160,340 Americans died of
Lung cancer is the most common cause of cancer-related death in the United
States, both for men and for women.[ii] Those with localized disease at diagnosis have a better survival rate
at 5 years (52.2%) than those with metastatic disease (3.7%), but the
figures are still pretty discouraging.
Two major types of lung cancer are diagnosed:
The National Cancer Institute database has excellent articles on conventional
diagnosis and treatment recommendations for both
Non-Small Cell and
Small-Cell lung cancer.
Conventional treatments have not been spectacularly successful for lung
cancer, whether of the bronchogenic smoking-associated or the adenocarcinoma
not associated with smoking. In a study of four different chemotherapy
regimens published in the
New England Journal of Medicine in 2002[iii], the median one-year survival was 33% and 2-year survival was 11%. One
regimen (gemcitabine plus cisplatin) did show significantly longer survival,
but with severe kidney toxicity because of the high doses of the platinum-based
So... are there any alternatives to the conventional treatment?
A recent paper by Dr. Lasalvia-Prisco discusses the necessary conditions
for cancer survival and progression:
"Chemotherapy aims to control the number and proliferation of cancer
cells, but it does not effectively control the two best-known conditions
of the tumor-permissive environment: neoangiogenesis and tolerogenic immunity."[iv] The patients in this study showed significant increase in survival when
treated with the addition of anti-angiogenesis therapies and a tumor vaccine.
In recent years efforts are being made in conventional oncology to exploit
the body's immune system by forcing the dendritic (otherwise known
as antigen-presenting) cells to complex with various cancer-produced proteins,
in an effort to stimulate the body to produce antigens to the tumor. These
efforts have been greeted with incomplete success, largely because the
cancer cells are so quick to mutate. The vaccine that works this month
may be totally ineffective next month. Nevertheless, cancer vaccines have
been shown to have some success, resulting in increased survival times.[v],
Of course, none of the patients in these studies was advised to do anything
about diet or lifestyle, and these variables were not controlled for.
And the vaccines were made to work against the solid tumor with which
the patients were initially diagnosed, not against the circulating tumor
cells which result in metastatic disease.
At the Arizona Center for Advanced Medicine, we use a combination of modalities
to treat our patients.
The quality of life during treatment is good. Almost all of our patients
(unless they have had prior conventional chemotherapy) keep their hair,
maintain their blood counts, and improve their physical function and well-being
within a very short time of starting therapy. Our
Integrative Cancer Treatment can improve your health and induce long term remission of disease.
Office: 8841 E Bell Road
Scottsdale, AZ 85260
Tel: (480) 240-2600
Fax: (480) 240-2601
Monday – Friday: 9am – 5pm
Call us to make an appointment to tour the Center and meet the staff.
http://www.cdc.gov/cancer/lung/statistics/ Downloaded 11/2/2013
[ii] Siegel R, Naishadham D, Jemal A.
Cancer statistics, 2012.
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138.
[iii] Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu
J, Johnson DH.
Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2002 Jan 10;346(2):92-8.
[iv] Lasalvia-Prisco E, Goldschmidt P, Galmarini F, Cucchi S, Vázquez
J, Aghazarian M, Lasalvia-Galante E, Golomar W, Gordon W.
Addition of an induction regimen of antiangiogenesis and antitumor immunity
to standard chemotherapy improves survival in advanced malignancies.
Med Oncol. 2012 December; 29(5): 3626-3633. doi: 10.1007/s12032-012-0301-1
[v] Lasalvia-Prisco E, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar
W, Gordon W.
Antitumoral effect of a vaccination procedure with an autologous hemoderivative.
Cancer Biol Ther. 2003 Mar-Apr;2(2):155-60.
[vi] Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C,
Olver CS, Lencioni AM, Dusto NL, Tal A, Har-Noy M, Lillehei KO, Katsanis
E, Graner MW.
Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog
treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine.
Int J Hyperthermia. 2013 Aug;29(5):390-8. doi: 10.3109/02656736.2013.800997.